Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. more
Time Frame | SYRE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.08% | -2.12% | -3% |
1-Month Return | -13.24% | -3.42% | -0.73% |
3-Month Return | -20.91% | -11.13% | 2.87% |
6-Month Return | -6.91% | -5.74% | 7.17% |
1-Year Return | 53.44% | 3.97% | 25.31% |
3-Year Return | -77.22% | 1.05% | 28.38% |
5-Year Return | -87.01% | 34.37% | 81.89% |
10-Year Return | -90.23% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 18.74M | 2.33M | 886.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":12.43,"profit":true},{"date":"2023-12-31","value":4.73,"profit":true}] |
Cost of Revenue | 901.00K | 1.62M | 2.00M | 1.96M | 964.00K | [{"date":"2019-12-31","value":45.03,"profit":true},{"date":"2020-12-31","value":81.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.15,"profit":true},{"date":"2023-12-31","value":48.18,"profit":true}] |
Gross Profit | (901.00K) | (1.62M) | 16.74M | 365.00K | (78.00K) | [{"date":"2019-12-31","value":-5.38,"profit":false},{"date":"2020-12-31","value":-9.7,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":2.18,"profit":true},{"date":"2023-12-31","value":-0.47,"profit":false}] |
Gross Margin | - | - | 89.32% | 15.67% | (8.80%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":17.55,"profit":true},{"date":"2023-12-31","value":-9.86,"profit":false}] |
Operating Expenses | 79.43M | 81.48M | 84.39M | 87.11M | 243.19M | [{"date":"2019-12-31","value":32.66,"profit":true},{"date":"2020-12-31","value":33.51,"profit":true},{"date":"2021-12-31","value":34.7,"profit":true},{"date":"2022-12-31","value":35.82,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (80.33M) | (81.48M) | (65.65M) | (84.78M) | (242.30M) | [{"date":"2019-12-31","value":-8033400000,"profit":false},{"date":"2020-12-31","value":-8148100000,"profit":false},{"date":"2021-12-31","value":-6564900000,"profit":false},{"date":"2022-12-31","value":-8478100000,"profit":false},{"date":"2023-12-31","value":-24230300000,"profit":false}] |
Total Non-Operating Income/Expense | 3.56M | 1.18M | 100.00K | 1.67M | (90.37M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":33.19,"profit":true},{"date":"2021-12-31","value":2.81,"profit":true},{"date":"2022-12-31","value":46.85,"profit":true},{"date":"2023-12-31","value":-2539.8,"profit":false}] |
Pre-Tax Income | (78.25M) | (80.89M) | (65.66M) | (83.95M) | (338.82M) | [{"date":"2019-12-31","value":-7825400000,"profit":false},{"date":"2020-12-31","value":-8089300000,"profit":false},{"date":"2021-12-31","value":-6566000000,"profit":false},{"date":"2022-12-31","value":-8395100000,"profit":false},{"date":"2023-12-31","value":-33881600000,"profit":false}] |
Income Taxes | - | (593.00K) | 141.00K | (136.00K) | (26.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-420.57,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-96.45,"profit":false},{"date":"2023-12-31","value":-18.44,"profit":false}] |
Income After Taxes | - | (80.30M) | (65.80M) | (83.81M) | (338.79M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8030000000,"profit":false},{"date":"2021-12-31","value":-6580100000,"profit":false},{"date":"2022-12-31","value":-8381500000,"profit":false},{"date":"2023-12-31","value":-33879000000,"profit":false}] |
Income From Continuous Operations | (83.21M) | (80.89M) | (65.80M) | (83.81M) | (338.79M) | [{"date":"2019-12-31","value":-8321400000,"profit":false},{"date":"2020-12-31","value":-8089300000,"profit":false},{"date":"2021-12-31","value":-6580100000,"profit":false},{"date":"2022-12-31","value":-8381500000,"profit":false},{"date":"2023-12-31","value":-33879000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (78.25M) | (80.89M) | (65.80M) | (83.81M) | (338.79M) | [{"date":"2019-12-31","value":-7825400000,"profit":false},{"date":"2020-12-31","value":-8089300000,"profit":false},{"date":"2021-12-31","value":-6580100000,"profit":false},{"date":"2022-12-31","value":-8381500000,"profit":false},{"date":"2023-12-31","value":-33879000000,"profit":false}] |
EPS (Diluted) | (61.25) | (40.25) | (25.00) | (25.33) | (74.19) | [{"date":"2019-12-31","value":-6125,"profit":false},{"date":"2020-12-31","value":-4025,"profit":false},{"date":"2021-12-31","value":-2500,"profit":false},{"date":"2022-12-31","value":-2533,"profit":false},{"date":"2023-12-31","value":-7419,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SYRE | |
---|---|
Cash Ratio | 7.20 |
Current Ratio | 7.32 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SYRE | |
---|---|
ROA (LTM) | -38.81% |
ROE (LTM) | -91.62% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SYRE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.22 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.78 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SYRE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 2209.92 |
P/B | 7.91 |
Price/FCF | NM |
EV/R | 1964.91 |
EV/Ebitda | NM |
Spyre Therapeutics Inc. (SYRE) share price today is $23.86
Yes, Indians can buy shares of Spyre Therapeutics Inc. (SYRE) on Vested. To buy Spyre Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SYRE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Spyre Therapeutics Inc. (SYRE) via the Vested app. You can start investing in Spyre Therapeutics Inc. (SYRE) with a minimum investment of $1.
You can invest in shares of Spyre Therapeutics Inc. (SYRE) via Vested in three simple steps:
The 52-week high price of Spyre Therapeutics Inc. (SYRE) is $47.97. The 52-week low price of Spyre Therapeutics Inc. (SYRE) is $17.83.
The price-to-earnings (P/E) ratio of Spyre Therapeutics Inc. (SYRE) is
The price-to-book (P/B) ratio of Spyre Therapeutics Inc. (SYRE) is 7.91
The dividend yield of Spyre Therapeutics Inc. (SYRE) is 0.00%
The market capitalization of Spyre Therapeutics Inc. (SYRE) is $1.36B
The stock symbol (or ticker) of Spyre Therapeutics Inc. is SYRE